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Purpose: Blood pressure (BP), age, and reduced renal function are major risk factors for white-
matter lesions (WMLs) in the general population. However, it remains unclear whether or not 
the BP itself or other parameters related to the BP are associated with WMLs in hypertensive 
patients with well-controlled BP. We investigated the relationships of the presence of WMLs 
with the central systolic BP (cSBP) and estimated glomerular filtration rate (eGFR) in treated 
hypertensive patients.
Method: We studied 185 hypertensive patients with median duration of hypertension, 10.0 years, 
whose BP is controlled to SBP and diastolic BP (DBP) of 139 ± 17 and 79 ± 10 mmHg, 
respectively. We measured cSBP and brain magnetic resonance imaging (MRI) was examined 
within 2 weeks after last BP and biological measurements.
Results: Patients with higher-grade WMLs, as assessed by the presence of Scheltens deep 
white-matter hyperintensity (SDWMH) in the frontal (grade 0–2 vs 3–6) and parietal areas 
(grade 0–2 vs 3–6) where small arteries are affected at earlier stage of hypertension, as well 
as that of Fazekas deep white-matter hyperintensity (FDWMH) (grade 2–3 vs 0–1) and Fazekas 
periventricular hyperintensity (FPVH) (grade 1–3 vs 0) were older, had higher serum creatinine 
levels, a longer duration of hypertension, and lower eGFR values. The grade of the WMLs 
was not associated with either the cSBP or the brachial SBP. In logistic regression analyses 
after adjustment for age, sex, cSBP, and hypertension duration, showed significant association 
between eGFR and WMLs. The patients with lower eGFR (,60 mL/minute/1.73 m2) tended to 
have higher grade WMLs. The odds ratio was 2.87 for FDWMH (P = 0.017), 1.99 for FPVH 
(P = 0.131), and 2.33 for SDWMH in the parietal area (P = 0.045).
Conclusion: Presence of WMLs was associated with eGFR, but not with either the brachial 
SBP or cSBP in hypertensive patients with well-controlled BP.
Keywords: white-matter lesions, central systolic blood pressure, estimated glomerular 
filtration rate
Introduction
White-matter lesions (WMLs) are frequently observed on cerebral magnetic resonance 
imaging (MRI) of elderly patients without apparent neurological symptoms. In addition 
to age, hypertension has also been consistently reported to be a common risk factor for 
the development of cerebral WMLs.1–3 The association between hypertension and the 
development of WMLs has been established in cross-sectional4 as well as longitudinal 
studies.1 Several studies have examined the prevalence of WMLs in hypertensive and 
high-normotensive subjects.5,6 White-matter hyperintensities (WMHs) seen on MRI 
scans are associated with degenerative changes in the arterioles that are related to 
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atherosclerosis, suggesting that cerebral arteriosclerosis of 
the penetrating vessels is a major factor in the pathogenesis 
of ischemic WMLs.4
Recently, several noninvasive parameters have been 
described for the assessment of vascular stiffness. Central 
systolic blood pressure (cSBP) and the augmentation index 
(AI) are parameters that can be estimated noninvasively from 
the central arterial waveforms through radial arterial pulse 
wave analysis.7–9 AI and cSBP are reported to be closely 
related to several risk factors for atherosclerosis and future 
cardiovascular events.9–11
A recent study showed that the cSBP was more strongly 
correlated with the presence of WMLs than the brachial 
systolic blood pressure (brachial SBP).12
Recently, the relationship between chronic kidney disease 
(CKD) and cardiovascular disease has also been highlighted. 
Furthermore, recent studies have reported the existence of 
an association between CKD (lower estimated glomerular 
filtration rates [eGFR]) and the presence of WMLs.13,14 Renal 
dysfunction may be related to cerebral small vessel disease, 
for example WMLs.
Therefore, this study chose cSBP and eGFR as variables 
of interest. The association of WMLs with cSBP and eGFR 
in treated hypertensive patients has not yet been studied. 
Correlations between the presence of subcortical WMLs and 
clinical parameters have also not been studied yet.
In this study, we investigated the relationships of the 




Study participants were recruited from hypertensive patients 
under treatment with antihypertensive medications. They 
were outpatients of the Jingumae Clinic from June 2010 
to February 2011. All study participants were aged over 
60 years. The exclusion criteria included inability to apply 
the tonometric system for evaluation, such as in patients with 
atrial fibrillation, and inability to perform MRI, as in patients 
with pacemakers and other implants. Informed consent was 
obtained from all participants prior to study enrollment. The 
present study was performed under approval of the clinical 
research protocol by the institutional ethics committee of 
Nara medical university, and in compliance with the Helsinki 
Declaration of 1975. Among the 200 participants who agreed 
with the study objectives and protocols of the study and pro-
vided written consent to undergo all the procedures, 15 were 
excluded due to the aforementioned MRI contraindications 
or because they had atrial fibrillation, which made use of the 
tonometric system impossible.
MRI examinations
MRI was performed at one of two centers with a 1.5-T 
clinical MR unit (Magnetom Avanto; Siemens AG, Erlangen, 
Germany) equipped with an 8-channel phased array coil, 
or with a 1.5-T clinical MR unit (GE Signa HDx; General 
Electric, Harvey, USA) equipped with a 12-channel phased 
array coil. All examinations included axial sections of 
conventional spin-echo T1-weighted (TR = 560 to 2100 ms, 
TE = 8.8 to 12 ms), spin-echo T2-weighted (TR = 3934 to 
4000 ms, TE = 94 to 110 ms), and fluid-attenuated inversion 
recovery (FLAIR; TR = 8400 to 10,000 ms, TI = 2100 
to 2600 ms, TE = 110 to 125 ms) sequences. The slice 
orientation was the axial plane perpendicular to the posterior 
margin of the pons, and the slice thickness was 5 mm with a 1 
or 2 mm gap. Images were obtained using a 256 × 256 matrix 
or 352 × 352 matrix and a 230 mm field of view.
Assessment of deep white-matter 
hyperintensities and periventricular 
hyperintensities
WMLs consist of deep white-matter hyperintensities 
(DWMH) and periventricular hyperintensities (PVH). 
DWMH assessment was performed centrally by a single 
rater blinded to the clinical data of the study participants . 
The severity of the WMHs was rated visually on axial FLAIR 
images using the Fazekas scale15 (absent, grade 0; punctuate, 
grade 1; early-confluent, grade 2; confluent, grade 3) and 
Scheltens rating scale16 (range, 0 to 30), in which scores 0 to 
6 are given for four subcortical white-matter regions (frontal, 
parietal, temporal, occipital), and scores from 0 to 2 for 3 
periventricular regions (frontal caps, occipital caps, bands). 
Basal ganglia and infratentorial hyperintensities were not 
rated for this study.
PVHs were graded as 0 = absence, 1 = ‘caps’ or pencil-
thin lining, 2 = smooth ‘halo’, 3 = irregular PVH extending 
into the deep white matter using the Fazekas scale15, and 
scored from 0 to 2 for three periventricular lesions using the 
Scheltens rating scale.16
Grade 2 or 3 DWMHs classified according to the Fazekas 
scale are progressive and likely malignant, whereas grades 0 
to 1 are not progressive.17,18 Grade 0 to 1 DWMHs as classi-
fied by the Fazekas scale are equivalent in severity to grades 
0, 1, and 2 as classified by Scheltens rating scale.16 Therefore, 
we divided patients with DWMHs into two clinical groups 
according the lesion grade.
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Grade 0 PVH represents the normal condition, whereas 
grades 1, 2, 3 PVHs are abnormal. Therefore, we also divided 
patients with PVHs into two groups according to the severity 
grade of the lesions.
Measurement of the CBP and AIx@75
Measurements of the CBP and AI corrected to a heart 
rate of 75 bpm (AIx@75) were performed as described 
  previously.19 The pulse pressure waveform of the radial 
artery was recorded using an automated tonometry system 
(HEM-9000AI; Omron Healthcare, Kyoto, Japan) with the 
patient in the sitting position after having rested for at least 
5 minutes. The waveform was automatically calibrated using 
the built-in oscillometric brachial sphygmomanometer, and 
the peak and trough of the radial pressure wave were adjusted 
for the brachial SBP and diastolic blood pressure (DBP), 
respectively. The second peak (late systolic inflection) was 
automatically detected by an algorithm programmed into the 
HEM-9000AI system using the second maxima of the fourth 
derivative of the radial pressure waveform to determine the 
radial AI, as well as the late or second SBP (SBP2). This algo-
rithm is described in greater detail elsewhere.20 The height 
of the second peak corresponds to the SBP2 value obtained 
using HEM-9000AI. The value of SBP2 is very similar to 
that of aortic CBP recorded using invasive techniques;21 and 
thus, SBP2 was used as an estimate of CBP. CBP determined 
using HEM9000-AI is comparable to that determined using 
a generalized aorta–radial transfer function.22,23 The AI was 
calculated using the following formula: (SBP2 – DBP)/(the 
first peak SBP – DBP) × 100. Because the AI is influenced by 
the heart rate, AI was normalized for a heart rate of 75 bpm 
(AIx@75), as proposed by Wilkinson et al.24 In this study, 
these measurements were performed by a single highly 
experienced investigator.
Statistical analyses
We presented categorical variables as numbers and 
percentages and assessed the differences in the categorical 
variables according to the MRI scores using the chi-
square test, while describing continuous variables as mean 
values ± standard deviations, unless otherwise indicated. 
Based on their distribution, we estimated the differences 
in the continuous variables according to the MRI scores by 
Student’s t-test or the Wilcoxon’s rank sum test. We used 
logistic regression analyses to assess the association between 
high MRI scores and low eGFR (,60 mL/minute/1.73 m2) 
adjusted for age ($70 years), sex, cSBP ($140 mmHg) 
and the quartile of hypertension duration. We performed all 
statistical analyses using JMP software (v. 9.0; SAS Institute 
Inc, Cary, NC) and STATA (v. 10; Stata Corporation, College 
Station, TX). Differences at P values of less than 0.05 were 
considered to be statistically significant.
Results
The patient characteristics are shown in Table 1. In total, 
185 patients were included in this study, of which 84 (45%) 
were male. The mean (± standard deviation) age of the 
patients was 70 (±7) years. 3 (2%) had a history of myocardial 
infarction, 16 (9%) had a history of angina pectoris, 1 (0.5%) 
had a history of aortic disease, 1 (0.5%) had a history of 
peripheral arterial disease, and 8 (4%) had a history of heart 
failure. As for risk factors other than hypertension, 56 patients 
(30%) smoked habitually, 38 (21%) had diabetes mellitus, 
and 101 (55%) were dyslipidemic. Calcium-channel blockers, 
angiotensin-receptor blockers, angiotensin-converting 
enzyme, and β-blockers were used by 58%, 69%, 24%, and 
2% of the study participants, respectively.
The mean (± standard deviation) SBP was 139 (±17 mmHg, 
that of the cSBP was 143 (±20) mmHg, and that of AIx@75 
was 83% (±13)%.
The MRI study results are shown in Table 2. The 
WMLs were rated in severity visually on axial FLAIR 
images using the Fazekas scale;18 84% had grade 1 or 2 
FDWMHs, and 91% had grade 0 or 1 FPVHs. Using the 
Scheltens rating scale,19 85% had grade 0 lesions in the 
temporal region, whereas 89% had grade 1–6 lesions in 
the parietal region.
Comparison of the clinical parameters between WMLs 
with low and high Fazekas scores are shown in Table 3. 
The patients with higher-grade WMLs, (for both FDWMH 
[grade 2–3 versus 0–1] and FPVH [grade 1–3 versus 0]) 
were older, and had a higher serum creatinine level, a longer 
duration of hypertension, and a lower eGFR. The WML grade 
was not associated with either the cSBP or brachial SBP. 
Comparison of the clinical parameters between patients with 
WMLs assigned low and high Scheltens scores are shown in 
Table 4. The patients with higher-grade WMLs (both frontal 
SDWMH [grade 0–2 versus 3–6] and parietal SDWMH 
[grade 0–2 versus 3–6]) were older, and had a higher serum 
creatinine level, a longer duration of hypertension, and a 
lower eGFR. The WML grade was not associated with either 
the cSBP or the brachial SBP.
Logistic regression analyses were conducted to assess the 
association of the MRI scores with the eGFR after adjustment 
for age, sex, cSBP, and history of hypertension. The patients 
with lower eGFR values (,60 mL/minute/1.73 m2) tended 
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to have higher-grade WMLs. The odds ratio for FDWMH 
(grade 2–3 versus 0–1) was 2.87 (P = 0.017), that for FPVH 
(grade1–3 versus 0) was 1.99 (P = 0.131), and that for 
SDWMH in the parietal (grade 3–6 versus 0–2) area was 
2.38 (P = 0.045).
Discussion
Among the major factors associated with the development of 
WMLs is high blood pressure. It was recently reported that 
the cSBP is correlated more strongly with WMLs than the 
brachial SBP, and that the cSBP is a better predictor of WMLs 
than the brachial SBP in relatively early stages of WMLs.12 
Another study found that the cSBP was significantly associ-
ated with the presence of intracerebral small vessel disease in 
an apparently healthy general population.25 Both were cross-
sectional observational studies of the general population.
However, more than 50% of the subjects in these studies 
had normal blood pressure, and most were not receiving treat-
ment with antihypertensive drugs. Our study involved only 
hypertensive patients, and all were receiving antihypertensive 
drugs. To the best of our knowledge, there have been no prior 
studies of the relationship between the cSBP and WMLs in 
hypertensive patients under treatment with antihypertensive 
agents. Under such conditions, WMLs are not affected by 
either the cSBP or brachial SBP. The lesions were associated 
with age, history of hypertension, and eGFR.
In addition, examination of the lesions by site demon-
strated that only WMLs in the temporal region26 with less 
prominent sclerotic changes of the medullary arteries showed 
no correlation with the eGFR, while correlations were evident 
for WMLs in regions with prominent sclerotic changes of 
the medullary arteries.
Despite being influenced by age, the eGFR showed a 
correlation with the presence of WMLs, even after adjust-
ment for age and history of hypertension (by multivariate 
analysis).
The presence of WMLs is significantly related to the risk 
of stroke, cognitive decline and dementia.27–29 The Northern 
Manhattan Study demonstrated that the WML volume is asso-
ciated with moderate-to-severe CKD, which was estimated 
using the serum creatinine and the Cockcroft–Gault formula, 
with eGFR values between 15 and 59 mL/min.13 Wada et al 
demonstrated that subjects with lower eGFR tended to have 
a larger number of lacunar infarcts and higher-grade WMLs; 
moreover, the mean grade of WMLs and the mean number 
of lacunar infarcts in subjects with albuminuria were greater 
than those in subjects without albuminuria.14 Our study also 
showed higher grades of WMLs in patients with lower eGFR 
values than in those with a higher eGFR. Furthermore, Wada 
et al also reported the existence of an association between 
urinary albumin levels and cerebral small vessel disease, 
independently of traditional cerebrovascular risk factors, 
in community-based elderly persons.30 In our study, the 
urinary protein excretion rate of our patients was very low, 
Table 1 Patient characteristics
Number of patients 185
Age year [Mean (SD)] 70 (7)
Male n (%) 84 (45)
Height cm [Mean (SD)] 157 (9)
Weight kg [Mean (SD)] 60 (11)
BMI kg/m2 [Mean (SD)] 24.3 (3.7)
Waist circumference cm [Mean (SD)] 88 (10)
Duration of hypertension [Median (Q1–Q4)] 10.0 (5.0–20.0)
Current smoking or past smoking n (%) 56 (30)
Current smoking n (%) 21 (11)
Regular alcohol drinkers n (%) 50 (27)
Hyperlipidemia n (%) 101 (55)
Diabetes mellitus n (%) 38 (21)
Hyperuricemia n (%) 18 (10)
Protenuria n (%) 6 (3)
Laboratory data
T-cho mg/dL [Mean (SD)] 202 (30)
TG mg/dL [Mean (SD)] 154 (89)
HDL-cho mg/dL [Mean (SD)] 55 (15)
LDL-cho (direct method) mg/dL [Mean (SD)] 117 (25)
LDL-cho (indirect method) mg/dL [Mean (SD)] 116 (28)
Serum creatinine mg/dL [Mean (SD)] 0.8 (0.2)
eGFR mL/min/1.73 m2 [Mean (SD)] 69.7 (14.7)
Past medical history
Cardiac infarction n (%) 3 (2)
Angina pectoris n (%) 16 (9)
Aortic disease n (%) 1 (0.5)
Peripheral artery disease n (%) 1 (0.5)
Heart failure n (%) 8 (4)
Blood pressure, heart rate, rAIx
SBP mmHg [Mean (SD)] 139 (17)
DBP mmHg [Mean (SD)] 79 (10)
PP mmHg [Mean (SD)] 60 (13)
HR/min [Mean (SD)] 72 (11)
SBP2 mmHg [Mean (SD)] 139 (18)
CSBP mmHg [Mean (SD)] 143 (20)
CPP mmHg [Mean (SD)] 64 (16)
rAIx% [Mean (SD)] 84 (15)
rAIx@75% [Mean (SD)] 83 (13)
Current medication
CCBs n (%) 107 (58)
β-blockers n (%) 4 (2)
ACE-Is n (%) 44 (24)
ARBs n (%) 128 (69)
Abbreviations: BMI, body mass index; Q1, #5 years; Q2, 5–10 years; Q3, 10–20 years; 
Q4,  .20  years;  T-cho,  total  lipoprotein  cholesterol;  TG,  triglyceride;  HDL-cho,   
high-density  lipoprotein  cholesterol;  LDL-cho,  low-density  lipoprotein 
cholesterol; eGFR, estimated glomerular filtration rate; SBP, brachial systolic blood 
pressure; DBP, brachial diastolic blood pressure; PP, brachial pulse pressure; HR, heart 
rate; SBP2, secondary systolic pressure; CSBP, central systolic blood pressure; CPP, 
central pulse pressure; rAIx, radial augmentation index; rAI×@75, radial augmentation 
index normalized for a heart rate of 75/minute; CCB, calcium channel blockers; ACE-
Is, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers.
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and urinary albumin was not determined. Similarly, Ikram 
et al investigated the relationship between kidney function 
as evaluated by the eGFR, and the occurrence of cerebral 
small-vessel disease by MRI analysis. They clearly showed 
that decreased eGFR was related to subclinical markers of 
cerebral small-vessel disease, such as deep white-matter vol-
ume and WMLs independently of cardiovascular risk factors 
such as age, sex, blood pressure, and diabetes.31 In our study 
as well, patients with lower eGFR values had higher-grade 
WMLs, even after adjustments for these risk factors, than 
those with a higher eGFR. Takahashi et al32 reported that 
mild renal dysfunction may be associated with an increase in 
the occurrence of cerebral small-vessel disease, independent 
of the presence of hypertension.
In our study also, lower eGFR was associated with higher 
grades of WMLs, independent of hypertension.
This study had limitations. First, hypertensive patients 
under treatment with various antihypertensive medications 
Table 2 Distribution of MRI findings in white-matter lesions
MRI findings Number of cases (%)
0 1 2 3
Fazekas scale
DWMH 14 (8) 96 (52) 60 (32) 15 (8)
PVH 83 (45) 86 (46) 15 (8) 1 (1)
0 1 2 3 4 5 6
Scheltens scale
DWMH
  Frontal 81 (44) 76 (41) 7 (4) 18 (10) 2 (1) 1 (1) 0 (0)
  Parietal 21 (11) 64 (35) 27 (15) 31 (47) 23 (11) 8 (4) 13 (7)
  Occipital 103 (56) 54 (29) 8 (4) 16 (9) 1 (1) 2 (1) 1 (1)
  Temporal 157 (85) 23 (12) 1 (1) 4 (3) 0 (0) 0 (0) 0 (0)
PVH caps
  Frontal 83 (45) 92 (50) 10 (5) – – – –
  Occipital 90 (49) 67 (36) 28 (15) – – – –
Lat ventricular bands 170 (94) 10 (5) 2 (1) – – – –
Abbreviations: DWMH, deep white-matter hyperintensities; PVH, periventricular hyperintensities.
Table 3 Comparison of clinical parameters between low and high Fazekas scores
Score grade FDWMH FPVH
0–1 2–3 P value 0 1–3 P value
Number of patients   110 75   83 102
Age (years) Mean (SD) 67 (5) 74 (6) ,0.0001 67 (5) 72 (7) ,0.0001
BMI (kg/m2) Mean (SD) 24.1 (3.6) 24.6 (3.9) 0.38 23.7 (3.3) 24.9 (4.0) 0.03
Male n (%) 49 (45) 35 (47) 0.78 39 (47) 45 (44) 0.7
Current or past smoking n (%) 34 (31) 22 (29) 0.82 29 (35) 27 (26) 0.21
Hyperlipidemia n (%) 60 (55) 41 (55) 0.99 49 (59) 52 (51) 0.27
Diabetes mellitus n (%) 23 (21) 15 (20) 0.88 18 (22) 20 (20) 0.73
SBP (mmHg) Mean (SD) 139 (17) 139 (16) 0.78 138 (16) 140 (17) 0.28
DBP (mmHg) Mean (SD) 79 (10) 78 (11) 0.58 79 (9) 79 (11) 0.67
PP (mmHg) Mean (SD) 60 (13) 61 (13) 0.77 58 (12) 62 (13) 0.059
CPP (mmHg) Mean (SD) 64 (16) 64 (15) 0.85 62 (16) 66 (16) 0.17
SBP2 (mmHg) Mean (SD) 129 (19) 131 (18) 0.6 128 (18) 132 (19) 0.17
CSBP (mmHg) Mean (SD) 144 (20) 142 (20) 0.66 142 (20) 144 (21) 0.4
rAIx (%) Mean (SD) 85 (16) 84 (12) 0.63 84 (15) 84 (14) 0.88
rAIx@75 (%) Mean (SD) 83 (13) 83 (12) 0.95 82 (13) 84 (13) 0.45
HR/min Mean (SD) 71 (12) 73 (10) 0.14 71 (12) 73 (10) 0.14
Serum creatinine (mg/dL) Mean (SD) 0.71 (0.16) 0.83 (0.24) ,0.0001 0.71 (0.16) 0.80 (0.23) 0.007
eGFR (mL/min/1.73 m2) Mean (SD) 74.1 (13.2) 63.2 (14.5) ,0.0001 74.3 (12.4) 65.9 (15.4) ,0.0001
Duration of hypertension (years) Median (interquartile range) 10 (5–15) 15 (8–20) 0.0002 10 (5–15) 12 (5.75–20) 0.0059
Abbreviation: FDWMH, deep white-matter hypertintensities of Fazekas scale; FPVH, periventricular hyperintensites of Fazekas scale; BMI, body mass index; SBP, brachial 
systolic blood pressure; DBP, brachial diastolic blood pressure; PP, brachial pulse pressure; CPP, central pulse pressure; SBP2, secondary systolic blood pressure; CSBP, central 
systolic blood pressure; rAIx, radial augmentation index; rAIx@75, radial augmentation index normalized for a heart rate of 75/min; HR, heart rate; eGFR, estimated 
glomerular filtration rate.
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were recruited. Calcium channel blockers were used 
by 58%, angiotensin-receptor blockers by 69%, and 
angiotensin-converting enzyme inhibitors by 24% of the 
study participants. The effects of medications on untreated 
hypertensive patients were not evaluated. Second, in our 
study, the methodology of WML assessment was performed 
using visual rating scale which was poorly substantiated and 
poorly undertaken. To evaluate of WML with precision, we 
should have used volumetric analysis that has been shown 
to be a superior method.
In conclusion, WMLs in patients with well-controlled 
BP were not found to be associated with either the central 
aortic blood pressure or the brachial blood pressure. Patients 
with lower eGFR values showed more marked progression 
of the WMLs than those with a higher eGFR. As to the sites 
of the WMLs, lesions in the frontal and parietal areas with 
prominent sclerotic changes of the medullary arteries were 
more advanced in the patients with lower eGFR values than 
in those with higher eGFR.
Disclosure
The authors have no conflicts of interest to declare in asso-
ciation with this work.
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